

Attorney Docket No.: DEX-0243
Inventors: Recipon et al.
Serial No.: 10/016,349
Filing Date: October 26, 2001
Page 2

This listing of the claims will replace all prior versions
and listings of claims in the application:

Listing of the claims:

Claim 1 (original): An isolated nucleic acid molecule
comprising

(a) a nucleic acid molecule comprising a nucleic acid
sequence that encodes an amino acid sequence of SEQ ID NO: 137
through 244;

(b) a nucleic acid molecule comprising a nucleic acid
sequence of SEQ ID NO: 1 through 136;

(c) a nucleic acid molecule that selectively hybridizes to
the nucleic acid molecule of (a) or (b); or

(d) a nucleic acid molecule having at least 60% sequence
identity to the nucleic acid molecule of (a) or (b).

Claim 2 (original): The nucleic acid molecule according to
claim 1, wherein the nucleic acid molecule is a cDNA.

Claim 3 (original): The nucleic acid molecule according to
claim 1, wherein the nucleic acid molecule is genomic DNA.

Claim 4 (original): The nucleic acid molecule according to
claim 1, wherein the nucleic acid molecule is a mammalian nucleic
acid molecule.

Attorney Docket No.: DEX-0243
Inventors: Recipon et al.
Serial No.: 10/016,349
Filing Date: October 26, 2001
Page 3

Claim 5 (original): The nucleic acid molecule according to claim 4, wherein the nucleic acid molecule is a human nucleic acid molecule.

Claim 6 (original): A method for determining the presence of a lung specific nucleic acid (LSNA) in a sample, comprising the steps of:

(a) contacting the sample with the nucleic acid molecule according to claim 1 under conditions in which the nucleic acid molecule will selectively hybridize to a lung specific nucleic acid; and

(b) detecting hybridization of the nucleic acid molecule to a LSNA in the sample, wherein the detection of the hybridization indicates the presence of a LSNA in the sample.

Claim 7 (original): A vector comprising the nucleic acid molecule of claim 1.

Claim 8 (original): A host cell comprising the vector according to claim 7.

Claim 9 (original): A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and (b) incubating the host cell under

Attorney Docket No.: DEX-0243
Inventors: Racipon et al.
Serial No.: 10/016,349
Filing Date: October 26, 2001
Page 4

conditions in which the polypeptide is produced.

Claim 10 (original): A polypeptide encoded by the nucleic acid molecule according to claim 1.

Claim 11 (original): An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence with at least 60% sequence identity to of SEQ ID NO: 137 through 244; or

(b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 136.

Claim 12 (original): An antibody or fragment thereof that specifically binds to the polypeptide according to claim 11.

Claim 13 (original): A method for determining the presence of a lung specific protein in a sample, comprising the steps of:

(a) contacting the sample with the antibody according to claim 12 under conditions in which the antibody will selectively bind to the lung specific protein; and

(b) detecting binding of the antibody to a lung specific protein in the sample, wherein the detection of binding indicates the presence of a lung specific protein in the sample.

Claim 14 (currently amended): A method for diagnosing and monitoring the presence and metastases of lung cancer in a

Attorney Docket No.: DEX-0243
Inventors: Recipon et al.
Serial No.: 10/016,349
Filing Date: October 26, 2001
Page 5

patient, comprising the steps of:

(a) determining an amount of the nucleic acid molecule of claim 1 or a polypeptide of ~~claim 6~~ claim 10 or 11 in a sample of a patient; and

(b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the lung specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of lung cancer.

Claim 15 (original): A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence the nucleic acid molecule of claim 1 or a polypeptide of claim 6 in a sample of a patient.

Claim 16 (original): A method of treating a patient with lung cancer, comprising the step of administering a composition according to claim 12 to a patient in need thereof, wherein said administration induces an immune response against the lung cancer cell expressing the nucleic acid molecule or polypeptide.

Claim 17 (original): A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 11.